Forxiga® (dapagliflozin): Risk of Diabetic Ketoacidosis During Treatment With Sodium Glucose Co-transporter 2 (SGLT2)Inhibitor - Dapagliflozin

User Rating: 2 / 5

Star ActiveStar ActiveStar InactiveStar InactiveStar Inactive

Date: 17 August 2015



A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals that serious cases of diabetic ketoacidosis (DKA) have been reported in patients on SGLT2 inhibitor treatment for type 2 diabetes. A number of these cases reported patients presenting with only moderately increased blood glucose levels. Such atypical presentation of DKA could delay diagnosis and treatment. Patients on SGLT2 inhibitors who present with symptoms of acidosis should be tested for ketones, to ensure quick diagnosis and management. Please refer to the DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Tuesday 26 October 2021, 16:44:37.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English

Choose Your Language